About Mediwhale
Mediwhale is a company based in Seoul (South Korea) founded in 2016 by Young G Lee, Kevin Taegeun Choi, and Tyler Hyungtaek Rim. Mediwhale has raised $36.18 million across 4 funding rounds from investors including Mirae Asset, Mayo Clinic and Korean Development Bank. Mediwhale offers products and services including Dr. Noon CVD, Dr. Noon CKD, Dr. Noon Fundus, and Dr. Noon Age. Mediwhale operates in a competitive market with competitors including RetInSight, Abyss Processing, BioScan AI, Deekh AI and NewVision Fundus, among others.
- Headquarter Seoul, South Korea
- Founders Young G Lee, Kevin Taegeun Choi, Tyler Hyungtaek Rim
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$36.18 M (USD)
in 4 rounds
-
Latest Funding Round
$13.18 M (USD), Series C
Mar 31, 2026
-
Investors
Mirae Asset
& 18 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mediwhale
Mediwhale offers a comprehensive portfolio of products and services, including Dr. Noon CVD, Dr. Noon CKD, Dr. Noon Fundus, and Dr. Noon Age.
Assesses cardiovascular disease risk from retinal images non-invasively.
Identifies chronic kidney disease risks through retinal scan analysis.
Screens for eye diseases like cataracts using automated retinal imaging.
Predicts biological age and mortality risk via retinal photographs.
Funding Insights of Mediwhale
Mediwhale has successfully raised a total of $36.18M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $13.18 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Mediwhale
Mediwhale has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Mirae Asset, Mayo Clinic and Korean Development Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital funds are managed to support unlisted companies' growth.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Mediwhale
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mediwhale
Investment portfolio details for Mediwhale
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Mediwhale
Detailed financials for Mediwhale
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mediwhale Comparisons
Peer comparison for Mediwhale
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mediwhale
Mediwhale operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RetInSight, Abyss Processing, BioScan AI, Deekh AI and NewVision Fundus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-based platform for diagnosis of eye disease
|
|
| Locked | Locked | Locked |
Delivers AI-based 3D image diagnosis for glaucoma detection by professionals.
|
|
| Locked | Locked | Locked |
AI-powered solutions for early detection of diseases using hardware and software.
|
|
| Locked | Locked | Locked |
Offers AI-based solutions for ophthalmology diagnostics and services.
|
|
| Locked | Locked | Locked |
Software for enhancing and storing medical images in ophthalmology field.
|
Detailed competitors of Mediwhale
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mediwhale
Complete news archive for Mediwhale
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mediwhale
Mediwhale was founded in 2016 and raised its 1st funding round 5 years after it was founded.
Mediwhale is headquartered in Seoul, South Korea.
Kevin Taegeun Choi is the current CEO of Mediwhale. They have also founded this company.
Mediwhale is a funded company, having raised a total of $36.18M across 4 funding rounds to date.
Mediwhale was founded in 2016 in Seoul, South Korea, as an AI-driven health technology firm. Operations focus on a diagnostic device that processes retinal images to estimate age, gender, height, and weight, while identifying biomarkers for conditions such as cardiovascular disease, chronic kidney disease, and retinal disorders. The company serves the medical diagnostics sector with tools aimed at early detection of chronic illnesses.
Mediwhale's top competitors include RetInSight, Deekh AI and Abyss Processing.
Mediwhale offers Dr. Noon CVD, Dr. Noon CKD, Dr. Noon Fundus, and Dr. Noon Age.
Mediwhale has 19 investors. Key investors include Mirae Asset, Mayo Clinic, Korean Development Bank, Arizona State University, and MedAxiom.